I. Introduction: The Engine Behind China's Drug Innovation Boom
Over the past decade, China's pharmaceutical industry has undergone a remarkable transformation โ from a manufacturer of generics to a global powerhouse of innovative drug development. In 2025, China approved 76 Class 1 innovative new drugs โ the highest number in its history. In the first half of 2026 alone, another 38 were approved, and out-licensing deals surpassed $110 billion.
Behind these headline numbers lies a critical, often overlooked factor: regulatory reform. Without sweeping changes to China's drug approval system, none of this innovation would have reached patients so quickly.
This article explores how China's regulatory reforms โ from the landmark 2015 State Council reforms to the latest IND 30-day silent approval pathway โ have fundamentally reshaped the country's drug development landscape, making China one of the fastest markets in the world for innovative drug approvals.
II. The Pre-Reform Era: A System in Need of Change
Before 2015, China's drug approval system was widely criticized for being slow, opaque, and inefficient.
Key problems included:
- Long approval times: Average NDA review took 26โ30 months โ far longer than in the U.S. or Europe.
- Massive application backlog: By 2015, the application backlog had ballooned to nearly 22,000 pending submissions.
- Generic drug dominance: Over 95% of approved drugs were generics; innovative drugs were rare.
- Low regulatory standards: Many applications lacked rigorous clinical data.
- Incentive misalignment: Domestic companies preferred to invest in "meโtoo" drugs rather than novel mechanisms, as the latter faced uncertain regulatory pathways and longer timelines.
The turning point came on August 18, 2015, when China's State Council issued Document No. 44 โ Opinions on Reforming the Evaluation and Approval System for Drugs and Medical Devices. This document marked the beginning of a decade-long regulatory revolution.
III. The Reform Timeline: A Decade of Transformation
2015 โ The Launch
| Date | Milestone |
|---|---|
| August 18, 2015 | State Council Document No. 44 launched the reform of drug and medical device evaluation and approval |
| November 2015 | NMPA (then CFDA) released implementation rules; priority review pilot programs began |
2016 โ System Overhaul
| Date | Milestone |
|---|---|
| March 2016 | CMC (chemical manufacturing and control) review standards were revised, reducing administrative burdens |
| June 2016 | Priority review and approval procedures formally established |
| September 2016 | The "104 Document" issued, setting new requirements for generic drug consistency evaluation โ widely seen as a "quality revolution" |
2017 โ China Joins ICH
| Date | Milestone |
|---|---|
| June 2017 | China officially joined the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) โ signaling that China's regulatory standards would align with global benchmarks |
2018 โ Institutional Consolidation
| Date | Milestone |
|---|---|
| March 2018 | CFDA (China Food and Drug Administration) was restructured and reorganized as the National Medical Products Administration (NMPA), with a clearer mandate and expanded authority |
| July 2018 | NMPA issued new guidelines for clinical trial applications, shortening review timelines |
| August 2018 | The Center for Drug Evaluation (CDE) announced a plan to reduce the review backlog to under 10,000 applications |
2019 โ The New Drug Law
| Date | Milestone |
|---|---|
| August 2019 | The revised Drug Administration Law was passed and took effect December 1, 2019. Key provisions included: drug marketing authorization holder (MAH) system, conditional approval pathway, and expedited approval for urgent clinical needs |
2020 โ Pandemic Acceleration
| Date | Milestone |
|---|---|
| January 2020 | Emergency use authorization (EUA) was introduced during the COVID-19 pandemic |
| March 2020 | NMPA further optimized the clinical trial application process, reducing timelines to 60 days |
| November 2020 | CDE issued new guidelines for breakthrough therapy designation |
2021 โ The IND 60-Day Era
| Date | Milestone |
|---|---|
| February 2021 | The IND 60-Day Silent Approval pathway was formally implemented. Clinical trial applications are automatically approved if no objection is raised within 60 working days |
| May 2021 | NMPA issued comprehensive guidance on the full reform of drug evaluation and approval |
2022โ2024 โ Refinement and Expansion
| Date | Milestone |
|---|---|
| 2022 | The conditional approval pathway was codified into formal regulations, with clear requirements for post-approval confirmatory studies |
| 2023 | Breakthrough therapy designation criteria were expanded; real-world data (RWD) and real-world evidence (RWE) guidelines were issued |
| 2024 | The IND 30-Day Channel was piloted for certain innovative drug categories, representing the next frontier in regulatory acceleration |
2025โ2026 โ The 30-Day Era and Beyond
| Date | Milestone |
|---|---|
| 2025 | The IND 30-Day Silent Approval channel was expanded to cover a broader range of innovative drug applications |
| 2025โ2026 | China approved 76 (2025) and 38 (H1 2026) Class 1 innovative drugs โ record numbers reflecting the cumulative impact of a decade of reform |
IV. The Four Accelerated Approval Pathways
China's regulatory system now offers four distinct expedited pathways for innovative drugs, each designed for different stages of development and levels of clinical urgency.
1. Priority Review and Approval (ไผๅ ๅฎก่ฏๅฎกๆน)
Introduced: 2016
Target: Drugs for serious diseases with significant clinical advantage, or drugs with urgent clinical need
Key Features:
- NDA review time: 10โ12 months (vs. standard 12โ16 months)
- Priority in queue for all review stages
- Dedicated communication channels with CDE
Eligibility:
- New innovative drugs (Class 1)
- Drugs for rare diseases
- Drugs for children
- New drugs for critical public health needs
Success Example: Furmonertinib's first-line NSCLC indication received priority review and was approved in record time.
2. Conditional Approval (้ๆกไปถๆนๅ)
Introduced: 2019 (formalized in the new Drug Administration Law)
Target: Drugs that can demonstrate significant therapeutic benefit based on surrogate endpoints or intermediate clinical endpoints in Phase II data
Key Features:
- Approval can be granted before full Phase III confirmatory data are available
- Post-approval, the company must complete confirmatory studies within a specified timeframe
- If confirmatory data are not positive, the approval may be withdrawn
Success Example: Lunkan Yilongtuo Monoclonal Antibody (BL-B01D1), the world's first approved bispecific ADC, received conditional approval based on Phase II PANKU-NPC 01 study data.
3. Breakthrough Therapy Designation (็ช็ ดๆงๆฒป็่ฏ็ฉ่ฎคๅฎ)
Introduced: 2020 (formalized in November 2020 guidelines)
Target: Drugs that demonstrate significant clinical improvement over existing therapies in Phase I or Phase II studies
Key Features:
- Intensive guidance from CDE throughout the development process
- Rolling review of NDA materials
- Potentially shorter overall development timelines
By the Numbers: By the end of 2024, CDE had granted breakthrough therapy designations to over 200 drug candidates. In H1 2026, multiple ADC and targeted therapy candidates received breakthrough designations, including HS-10504 (fourth-generation EGFR-TKI) and SHR-1826 (c-Met ADC).
4. Emergency Use Authorization (็ดงๆฅไฝฟ็จๆๆ)
Introduced: 2020 (during COVID-19)
Target: Drugs, vaccines, or medical devices for public health emergencies
Key Features:
- Rapid, temporary authorization based on limited data
- Conditional on public health need
- Authorization can be revoked once the emergency ends
Success Example: Multiple COVID-19 vaccines and therapeutics received EUA in 2020โ2022, paving the way for the broader application of expedited pathways.
V. The IND 30-Day Silent Approval Era
The IND (Investigational New Drug) silent approval mechanism has been one of the most transformative reforms.
How It Works
- Before Reform: Clinical trial applications had to wait for explicit CDE approval โ a process that could take months.
- 60-Day Silent Approval (2021): If CDE does not issue a "non-approval" decision within 60 working days of receiving a complete IND application, the application is automatically approved.
- 30-Day Silent Approval (2024โ2026): For select innovative drug categories, the silent window has been further shortened to 30 working days โ making China one of the fastest jurisdictions globally for IND approval.
Impact
- Faster trial initiation: Companies can start clinical trials weeks or months earlier than before.
- Reduced regulatory uncertainty: The silent approval mechanism provides clear, predictable timelines.
- Increased trial volume: China's 2,997 new drug clinical trials registered in 2025 โ the highest in its history โ reflect the impact of this reform.
VI. International Harmonization: China in the Global Regulatory Ecosystem
Joining ICH (2017)
China's accession to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) in June 2017 was a watershed moment.
What ICH Membership Means:
- China agreed to adopt ICH guidelines as the standard for drug development and review
- China's regulatory standards became interoperable with the U.S., EU, Japan, and other major markets
- Multinational companies gained confidence in China as a clinical trial destination
Mutual Recognition and Cooperation
- MRA with the EU: China and the EU have agreements on mutual recognition of certain GMP inspections.
- Collaboration with U.S. FDA: Regular bilateral meetings and data-sharing agreements.
- WHO Pre-qualification: Many Chinese drug manufacturers have achieved WHO pre-qualification for vaccines and essential medicines.
Global Impact
The harmonization of China's regulatory standards has been a key driver of:
- The $110 billion out-licensing boom in H1 2026 โ global pharma companies trust Chinese data quality
- Increased multinational clinical trials in China โ many global Phase III studies now include Chinese sites
- Chinese drugs going global โ with U.S. FDA approvals for drugs like taletrectinib, sunvozertinib, and penpulimab
VII. The Results: By the Numbers
| Metric | Pre-Reform (2014) | 2024 | 2025 | H1 2026 |
|---|---|---|---|---|
| Average NDA review time | 26โ30 months | 12โ16 months | 12โ16 months | 10โ12 months (priority) |
| IND approval time | 10โ14 months | 60 days (silent) | 60 days (silent) | 30 days (fast-track) |
| Class 1 innovative drugs approved | ~5โ10/year | 48 | 76 | 38 (H1) |
| Application backlog | ~22,000 | <2,000 | ~1,500 | <1,000 |
| Innovative drugs in global R&D (China-origin) | ~5% | ~28% | ~33% | ~37% |
Sources: NMPA, CDE annual reports, industry analysis
VIII. What This Means for International Patients
China's regulatory reforms have real, tangible benefits for patients โ including international patients seeking treatment in China.
Faster Access to Breakthrough Therapies
Because of the IND 30-day silent approval and conditional approval pathways, China is often among the first countries in the world where new therapies become available. For example:
- The world's first bispecific ADC (Lunkan Yilongtuo) was approved in China in June 2026 โ before any other jurisdiction.
- The world's first CAR-T for solid tumors (Shurui Jiao'ao) was approved in China in the same month.
- Multiple fourth-generation EGFR-TKIs and next-generation ADCs are in late-stage development in China, with approval expected soon.
World-Class Quality Standards
China's adoption of ICH guidelines means that drugs developed and approved in China meet global standards for quality, safety, and efficacy. International patients can have confidence that therapies available in China are comparable to those in the U.S. and Europe.
Competitive Pricing
Despite world-class quality, drug prices in China remain significantly lower than in Western countries. Combined with faster approval times, this makes China an increasingly attractive destination for patients seeking cutting-edge treatments.
Global Availability
The out-licensing boom means many Chinese-developed drugs are being commercialized by global pharma companies โ BMS, Merck, BioNTech, and others. What starts in China today may be available worldwide tomorrow.
IX. Future Outlook: The Next Phase of Reform
1. Real-World Evidence (RWE)
NMPA has issued guidelines on the use of RWD/RWE in drug development, particularly for post-approval studies and rare diseases. This will further accelerate access to new therapies.
2. Gene and Cell Therapy Guidelines
China is actively developing specific regulatory pathways for gene therapies, CAR-T, and other advanced therapeutic medicinal products (ATMPs) โ areas where China is becoming a global leader.
3. Digital Transformation
NMPA is investing in AI-powered review systems and electronic submission platforms, aiming to reduce administrative burdens and further shorten review timelines.
4. International Convergence
China continues to align its regulatory standards with those of the ICH and other international bodies, facilitating global drug development and improving international patient access to Chinese innovations.
X. Conclusion
China's drug regulatory reform has been nothing short of transformative. From the 2015 State Council reform to the IND 30-day silent approval and the four accelerated pathways, China has built one of the most efficient drug approval systems in the world.
The numbers tell the story:
- 76 Class 1 innovative drugs approved in 2025
- 38 in the first half of 2026
- $110 billion in out-licensing deals
- 33.7% of global innovative drug candidates now originate in China โ surpassing the U.S.
But beyond the numbers lies a more fundamental shift. China's regulatory system has moved from being a bottleneck to a catalyst for innovation. For international patients, this means faster access to world-class therapies, at competitive prices, with global-standard quality.
China is no longer just a manufacturing powerhouse for pharmaceuticals โ it is becoming the world's most dynamic regulatory environment for drug innovation.